Question 1

How does Cephalotaxus harringtonia work against leukemia?

Accepted Answer

Cephalotaxus harringtonia contains alkaloids called homoharringtonine and harringtonine that inhibit protein synthesis in cancer cells. These compounds bind to the ribosome's A-site, blocking peptide chain elongation during translation. This mechanism selectively targets rapidly dividing cells, including leukemia cells. The pharmaceutical drug omacetaxine mepesuccinate, derived from these alkaloids, is FDA-approved for chronic myeloid leukemia resistant to tyrosine kinase inhibitors. Evidence level: C for traditional use; pharmaceutical omacetaxine has established efficacy.

Question 2

Is Cephalotaxus harringtonia safe during pregnancy?

Accepted Answer

No, Cephalotaxus harringtonia is contraindicated during pregnancy. The plant contains cytotoxic alkaloids that inhibit protein synthesis and can cause fetal harm. The pharmaceutical derivative omacetaxine carries a black box warning for embryo-fetal toxicity. Women of childbearing potential must use effective contraception during treatment. Pregnant women should avoid all forms of this herb, including raw plant material and extracts. Evidence level: C for herb; pharmaceutical contraindication is established.

Question 3

What is the recommended dosage of Cephalotaxus harringtonia?

Accepted Answer

There is no established safe dosage for raw Cephalotaxus harringtonia. The plant contains toxic alkaloids with unpredictable concentrations that require pharmaceutical processing. Omacetaxine mepesuccinate, the FDA-approved derivative, is administered as a subcutaneous injection at 1.25 mg/m² twice daily during induction phases, strictly under medical supervision. Self-medication with raw herb preparations is strongly discouraged due to myelosuppression and hemorrhage risks. Evidence level: C for traditional use; pharmaceutical dosing is standardized.

Question 4

Does Cephalotaxus harringtonia interact with chemotherapy drugs?

Accepted Answer

Yes, significant interactions exist. Omacetaxine causes myelosuppression, so combining it with other bone marrow suppressants increases infection and bleeding risks. Concurrent use with anticoagulants or antiplatelet agents elevates hemorrhage risk. The raw herb should not be combined with any medications due to uncontrolled alkaloid content. Patients receiving chemotherapy should avoid this herb entirely unless under specialized oncology supervision. Evidence level: C for herb; pharmaceutical interactions are well-documented.

Question 5

What are the side effects of Cephalotaxus harringtonia?

Accepted Answer

The primary side effects include myelosuppression (low blood cell counts), increased bleeding risk, and hyperglycemia. Thrombocytopenia can lead to serious hemorrhage. Anemia and neutropenia increase infection susceptibility. Gastrointestinal effects and fatigue may occur. The raw plant carries additional risks from variable alkaloid concentrations and has caused toxicity in traditional use settings. Medical monitoring is essential during any treatment involving this plant's compounds. Evidence level: C for traditional use; pharmaceutical side effects are well-characterized.

Cephalotaxus harringtonia

Sources & Citations

Prunus avium

Physalis peruviana

CBD Source

Summary

Background

Traditional uses

Active compounds

Mechanism of action

Clinical evidence

Safety & adverse effects

Drug interactions

Evidence summary

PubMed sources

Government sources